Rep. Rick Larsen Unloads Abbott Laboratories (NYSE:ABT) Shares

Posted by Trevor Kearing on Jul 18th, 2026

Representative Rick Larsen (Democratic-Washington) recently sold shares of Abbott Laboratories (NYSE:ABT). In a filing disclosed on July 12th, the Representative disclosed that they had sold between $1,001 and $15,000 in Abbott Laboratories stock on July 8th. The trade occurred in the Representative’s “RICHARD R LARSEN IRA” account.

Representative Rick Larsen also recently made the following trade(s):

Purchased $1,001 – $15,000 in shares of Amphenol (NYSE:APH) on 7/8/2026.
Purchased $1,001 – $15,000 in shares of McKesson (NYSE:MCK) on 7/8/2026.
Sold $1,001 – $15,000 in shares of S&P Global (NYSE:SPGI) on 7/8/2026.

Abbott Laboratories Stock Up 1.9%

Abbott Laboratories stock traded up $1.88 during trading hours on Friday, hitting $100.71. The stock had a trading volume of 19,913,032 shares, compared to its average volume of 11,962,257. The company has a quick ratio of 1.01, a current ratio of 1.39 and a debt-to-equity ratio of 0.56. The stock has a market capitalization of $175.41 billion, a P/E ratio of 32.59, a price-to-earnings-growth ratio of 1.70 and a beta of 0.61. Abbott Laboratories has a 12-month low of $81.97 and a 12-month high of $137.49. The stock’s 50-day moving average price is $89.89 and its 200-day moving average price is $102.17.

Abbott Laboratories (NYSE:ABT – Get Free Report) last posted its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 EPS for the quarter, beating analysts’ consensus estimates of $1.28 by $0.03. The firm had revenue of $12.51 billion for the quarter, compared to analysts’ expectations of $12.52 billion. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.65%. The business’s revenue for the quarter was up 13.0% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.26 earnings per share. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Equities research analysts anticipate that Abbott Laboratories will post 5.48 EPS for the current fiscal year.

Abbott Laboratories Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th will be paid a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a yield of 2.5%. The ex-dividend date is Wednesday, July 15th. Abbott Laboratories’s dividend payout ratio (DPR) is currently 70.59%.

Insider Buying and Selling at Abbott Laboratories

In other Abbott Laboratories news, Director Daniel J. Starks acquired 10,000 shares of the business’s stock in a transaction dated Monday, April 27th. The stock was purchased at an average price of $92.65 per share, with a total value of $926,500.00. Following the transaction, the director directly owned 6,751,103 shares in the company, valued at approximately $625,489,692.95. The trade was a 0.15% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Philip P. Boudreau acquired 2,200 shares of Abbott Laboratories stock in a transaction dated Thursday, April 23rd. The stock was bought at an average price of $91.50 per share, with a total value of $201,300.00. Following the completion of the purchase, the chief financial officer directly owned 2,200 shares in the company, valued at $201,300. This represents a ∞ increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Company insiders own 0.46% of the company’s stock.

Institutional Trading of Abbott Laboratories

Hedge funds have recently bought and sold shares of the company. MidAtlantic Capital Management Inc. bought a new stake in shares of Abbott Laboratories during the 4th quarter valued at about $25,000. Cornerstone Financial Management LLC bought a new position in shares of Abbott Laboratories in the 4th quarter worth approximately $25,000. Purpose Unlimited Inc. purchased a new position in shares of Abbott Laboratories in the fourth quarter worth approximately $25,000. Portfolio Resources Advisor Group Inc. bought a new stake in Abbott Laboratories during the fourth quarter valued at approximately $26,000. Finally, Abound Financial LLC purchased a new stake in Abbott Laboratories during the fourth quarter valued at approximately $26,000. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Analyst Upgrades and Downgrades

ABT has been the topic of several recent analyst reports. Jefferies Financial Group cut their target price on Abbott Laboratories from $145.00 to $135.00 and set a “buy” rating on the stock in a research note on Friday, April 17th. Barclays lowered their price target on Abbott Laboratories from $144.00 to $143.00 and set an “overweight” rating on the stock in a report on Monday, April 20th. Benchmark reduced their price objective on Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating for the company in a report on Friday, April 17th. TD Cowen reissued a “buy” rating and issued a $115.00 target price on shares of Abbott Laboratories in a research report on Friday. Finally, Sanford C. Bernstein lowered their target price on shares of Abbott Laboratories from $125.00 to $110.00 and set an “outperform” rating on the stock in a research note on Friday, April 17th. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat, Abbott Laboratories has an average rating of “Moderate Buy” and a consensus price target of $118.61.

Check Out Our Latest Report on ABT

More Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

Positive Sentiment: Abbott beat Q2 earnings expectations and raised 2026 adjusted EPS guidance to $5.45-$5.60, signaling better profit momentum for the rest of the year. Abbott Reports Second-Quarter 2026 Results and Raises Full-Year EPS Guidance
Positive Sentiment: Management pointed to stronger second-half demand across multiple businesses, including nutrition, medical devices, diagnostics, and diabetes care, which supports a faster growth profile. ABT Q2 Earnings Call Flags Stronger Second-Half Setup
Positive Sentiment: Analysts turned more constructive after the results, with JPMorgan, Citi, Piper Sandler, Wells Fargo, TD Cowen, BTIG, and RBC all lifting targets or reaffirming bullish views. These Analysts Increase Their Forecasts On Abbott Following Better-Than-Expected Q2 Results

About Representative Larsen

Rick Larsen (Democratic Party) is a member of the U.S. House, representing Washington’s 2nd Congressional District. He assumed office on January 3, 2001. His current term ends on January 3, 2027.

Larsen (Democratic Party) is running for re-election to the U.S. House to represent Washington’s 2nd Congressional District. He declared candidacy for the 2026 election.

Since at least 2011, Larsen has been assigned to the Committee on Armed Services and the Committee on Transportation and Infrastructure.

Larsen’s first position as an elected official was in 1998 as a member of the Snohomish County Council.

Larsen earned his bachelor’s degree from Pacific Lutheran University. After earning his master’s degree in public affairs from the University of Minnesota, Larsen worked as the director of public affairs for the Washington State Dental Association and then as an economic development official with the Port of Everett. He went on to serve on the Snohomish County Council before seeking election to the U.S. House.

Abbott Laboratories Company Profile

(Get Free Report)

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.